par Sigoillot, Maud 
;Brockhoff, Anne;Meyerhof, Wolfgang;Briand, Loïc
Référence Applied microbiology and biotechnology, 96, 3, page (619-630)
Publication Publié, 2012-11
;Brockhoff, Anne;Meyerhof, Wolfgang;Briand, LoïcRéférence Applied microbiology and biotechnology, 96, 3, page (619-630)
Publication Publié, 2012-11
Article révisé par les pairs
| Résumé : | Sweet-tasting compounds are recognized by a heterodimeric receptor composed of the taste receptor, type 1, members 2 (T1R2) and 3 (T1R3) located in the mouth. This receptor is also expressed in the gut where it is involved in intestinal absorption, metabolic regulation, and glucose homeostasis. These metabolic functions make the sweet taste receptor a potential novel therapeutic target for the treatment of obesity and related metabolic dysfunctions such as diabetes. Existing sweet taste inhibitors or blockers that are still in development would constitute promising therapeutic agents. In this review, we will summarize the current knowledge of sweet taste inhibitors, including a sweet-taste-suppressing protein named gurmarin, which is only active on rodent sweet taste receptors but not on that of humans. In addition, their potential applications as therapeutic tools are discussed. |
